Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.60 |
| ▸ | PDE5A | O76074 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | C1R | P00736 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203940 | 0.85 | SLC2A1 (0.65) | ALDH1A1NPC1C1RRAB9ASMN1; SMN2 | |
| SCHEMBL2206804 | 0.83 | NPY5R (0.68) | TAAR1TRPA1SMN1; SMN2SLC2A1NPY5R | |
| SCHEMBL12510652 | 0.82 | KDM4E (0.46) | RAD52KMT2AALDH1A1SLC2A1NPY5R | |
| SCHEMBL2203694 | 0.82 | SLC2A1 (0.44) | RAD52KMT2ATRPA1ALDH1A1SLC2A1 | |
| SCHEMBL786130 | 0.80 | APP (0.56) | PDE5AKMT2ATRPA1SMN1; SMN2MAPT | |
| SCHEMBL31471948 | 0.80 | APP (0.56) | PDE5AKMT2ATRPA1SMN1; SMN2MAPT | |
| SCHEMBL11341927 | 0.80 | IGF1R (0.69) | TRPA1 | |
| SCHEMBL785429 | 0.79 | PDE5A (0.49) | PDE5AKMT2ATRPA1ALDH1A1MAPT | |
| SCHEMBL786005 | 0.79 | CYP1A2 (0.60) | PDE5AKMT2ATRPA1ALDH1A1MAPT | |
| SCHEMBL12175853 | 0.79 | KMT2A (0.71) | RAD52PDE5AKMT2ATAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4160389-B2 | — | — | 2008-10-01 | — | — | JP | claimed |
| CN-100340555-C | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2007-10-03 | — | — | CN | claimed |
| EP-1345925-B1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2006-05-17 | — | — | EP | claimed |
| US-6989385-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-24 | — | — | US | claimed |
| JP-2004516291-A | — | — | 2004-06-03 | — | — | JP | claimed |
| CN-1486312-A | Pyrazole compounds useful as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-03-31 | — | — | CN | claimed |
| EP-1345925-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-09-24 | — | — | EP | claimed |
| US-20030055068-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | claimed |
| WO-2002050065-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-06-27 | — | — | WO | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| US-20030055068-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | disclosed |
| US-20030036543-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-02-20 | — | — | US | disclosed |
| US-20030004161-A1 | Pyrazole compounds useful as protein kinase inhititors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-01-02 | — | — | US | disclosed |
| WO-2002066461-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002057259-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002050065-A2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004161-A1 | Pyrazole compounds useful as protein kinase inhititors | AURKC, AURKA, GSKIP | RAD52 3828/4885PDE5A 4266/4885KMT2A 1368/4885 |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | RAD52 1832/4885PDE5A 3115/4885KMT2A 1263/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | RAD52 1590/4885PDE5A 3262/4885KMT2A 1661/4885 |
| US-20030055068-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | RAD52 3011/4885PDE5A 4253/4885KMT2A 1000/4885 |
| US-20030036543-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | RAD52 2630/4885PDE5A 3588/4885KMT2A 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.